Leonardo Jaimes, MD

All articles by Leonardo Jaimes, MD

• Upcoming clinical trial will assess nucresiran in ATTR-CM

  A new clinical trial evaluating the efficacy of nucresiran in treating transthyretin amyloid cardiomyopathy (ATTR-CM) is set to launch soon.

• SGLTis associated with decreased mortality in ATTR-CM

  The use of SGLTis, a drug class commonly prescribed for diabetes and heart failure, appears to decrease mortality in ATTR-CM.

• New study examines how wild-type ATTR-CM differs in men and women

  There appear to be key differences between men and women regarding prevalence, prognosis, and survival in wild-type ATTR-CM.

• ATTR-CM cardiac muscle produces less force than expected, study finds

  Cardiac muscle (myocardium) in patients with ATTR-CM appears to have reduced contractile force compared to healthy cardiac muscle.

• Study examines arrhythmias in ATTR-CM, a frequent complication

  Arrhythmias appear to be a common complication in patients with ATTR-CM and may contribute to an increased risk of mortality.

• Artery dysfunction in ATTR-CM: An underestimated component?

  Abnormalities in the function of arteries and small blood vessels represent a key component of ATTR-CM pathology and a therapeutic target.

• Current and future insights in ATTR-CM management

  A recently published review summarized the advances in ATTR-CM screening, diagnosis and treatment and analyzed future perspectives. 

• Tafamidis improves ATTR-CM survival regardless of a patient’s age

  Tafamidis can improve survival in octogenarian patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

• Vutrisiran associated with better functional capacity in ATTR-CM

  Vutrisiran appears to effectively conserve functional capacity and quality of life (QOL) in patients with ATTR-CM.

• Acoramidis decreases hospitalization rate in ATTR-CM

  A new study reports that treatment with acoramidis decreases the rate of all-cause mortality and cardiovascular hospitalization in patients with ATTR-CM.